Last Updated : July 24, 2024
Details
Generic Name:
clofarabine
Project Status:
Not filed
Therapeutic Area:
Acute lymphoblastic leukemia
Manufacturer:
Sanofi-aventis Canada Inc.
Brand Name:
Clolar
Project Line:
Reimbursement Review
Project Number:
NS0020-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024